Thermo Fisher Scientific Inc. announced the launch of the international CorEvitas Adolescent Alopecia Areata (AA) Registry, addressing a critical unmet need for real-world, adolescent-specific evidence and data related to this autoimmune disease. The registry is now active in both Europe and the U.S., with the first patient in North America enrolled in late 2024.
This initiative aims to enable research to better understand the burden of disease for AA patients, as well as the real-world effectiveness and safety of newly approved treatments. The registry is the 12th independent registry from CorEvitas, part of Thermo Fisher Scientific’s PPD clinical research business, complementing an existing adult AA registry launched in 2023.
The registry is designed to prospectively study alopecia areata, including the incidence of safety events of interest, medication utilization patterns, and the comparative safety and effectiveness of treatments. It will also gather data on the history of AA in adolescents and their growth and development over time while undergoing treatment with new therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.